SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-307293"
 

Sökning: id:"swepub:oai:DiVA.org:uu-307293" > Sequence variation ...

Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients

Sclafani, Francesco (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Chau, Ian (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Cunningham, David (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
visa fler...
Lampis, Andrea (författare)
Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
Hahne, Jens Claus (författare)
Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
Ghidini, Michele (författare)
Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
Lote, Hazel (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
Zito, Domenico (författare)
Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
Tabernero, Josep (författare)
Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona 08035, Spain.
Glimelius, Bengt (författare)
Uppsala universitet,Experimentell och klinisk onkologi
Cervantes, Andres (författare)
Univ Valencia, Biomed Res Inst INCLIVA, Dept Haematol & Med Oncol, Valencia 46010, Spain.
Begum, Ruwaida (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
De Castro, David Gonzalez (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Wilson, Sanna Hulkki (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Peckitt, Clare (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Eltahir, Zakaria (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Wotherspoon, Andrew (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Tait, Diana (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Brown, Gina (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Oates, Jacqueline (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
Braconi, Chiara (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Canc Therapeut, Sutton SM2 5NG, Surrey, England.
Valeri, Nicola (författare)
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
visa färre...
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England. (creator_code:org_t)
2016-07-05
2016
Engelska.
Ingår i: Carcinogenesis. - : Oxford University Press (OUP). - 0143-3334 .- 1460-2180. ; 37:9, s. 852-857
Relaterad länk:
https://academic.oup...
visa fler...
https://urn.kb.se/re...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP in mature miR-608 and clinical outcome in CRC. Here, we analyzed the association between rs4919510 and benefit from perioperative treatment in a randomised phase II trial of neoadjuvant Capecitabine and Oxaliplatin (CAPOX) followed by chemo-radiotherapy, surgery and adjuvant CAPOX +/- Cetuximab in high-risk locally advanced rectal cancer (LARC). A total of 155/164 (94.5%) patients were assessable. 95 (61.3%) were homozygous for CC, 55 (35.5%) heterozygous (CG) and 5 (3.2%) homozygous for GG. Median follow-up was 64.9 months. In the CAPOX arm the 5-year progression-free survival (PFS) and overall survival (OS) rates were 54.6% and 60.7% for CC and 82.0% and 82.1% for CG/GG, respectively (HR PFS 0.13, 95% CI: 0.12-0.83, P = 0.02; HR OS 0.38, 95% CI: 0.14-1.01, P = 0.05). In the CAPOX-C arm PFS and OS were 73.2 and 82.2%, respectively for CC carriers and 64.6 and 73.1% for CG/GG carriers (HR PFS 1.38, 95% CI: 0.61-3.13, P = 0.44; HR OS 1.34, 95% CI: 0.52-3.48, P = 0.55). An interaction was found between study treatment and rs4919510 genotype for both PFS (P = 0.02) and OS (P = 0.07). This is the first study investigating rs4919510 in LARC. The CC genotype appeared to be associated with worse prognosis compared to the CG/GG genotype in patients treated with chemotherapy and chemo-radiotherapy alone. Addition of Cetuximab to chemotherapy and chemo-radiotherapy in CC carriers appeared to improve clinical outcome.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy